Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Atopix Awarded Biomedical Catalyst Grant

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
£1.7 million grant to study an innovative anti-allergic approach to the treatment of atopic dermatitis.

Atopix Therapeutics Ltd (“Atopix”) has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

Atopix has acquired rights to OC459 and other CRTH2 antagonists from Oxagen Ltd.

OC459 has successfully completed proof-of-concept clinical trials in asthma and allergic rhinoconjunctivitis.

OC459 is a highly potent and selective CRTH2 antagonist which is effective in asthma when given once a day at doses as low as 25 mg.

CRTH2 is a G protein coupled receptor that is selectively expressed by key cell types mediating allergic responses - Th2 lymphocytes, basophils and eosinophils - and is activated by prostaglandin D2, an abundant lipid product of mast cells.

Mast cell-dependent activation of Th2 lymphocytes and eosinophils is blocked by CRTH2 antagonists which reduce both allergic sensitization and effector responses to allergen.

The prostaglandin D2/CRTH2 pathway is up-regulated in severe allergic conditions and functional polymorphisms in CRTH2 are associated with asthma and atopic dermatitis.

Atopix now plans to study the effect of once daily treatment with OC459 for 6 months in patients with atopic dermatitis whose condition is poorly controlled by existing therapies.

The study is powered to detect an effect on flares, the major health economic burden in atopic dermatitis. The primary endpoint of the study will be the Eczema Activity Severity Index. Atopix will also determine whether functional genetic polymorphisms in CRTH2 influence the therapeutic response to OC459.

The award from the Biomedical Catalyst follows a £3.7 million Series A funding led by MPM Capital, SV Life Sciences and Wellington Partners with additional participation by Bessemer Partners and Red Abbey.

In connection with the financing Luke Evnin, Managing Director of MPM Capital, Mike Carter Venture Partner at SV Life Sciences and Regina Hodits, General Partner at Wellington Partners have joined Tim Edwards (Chairman), Mark Payton (CEO), Alan Ezekowitz, CEO and Chairman of Abide Therapeutics and former SVP Respiratory and Immunology franchise at Merck Research Laboratories and Sir John Bell, Regius Professor of Medicine at Oxford University as members of the Board.

Mark Payton, CEO of Atopix, said: “In the past six months, Atopix has transformed itself from a semi-virtual to a fully formed clinical stage biopharmaceutical company. This award from the Biomedical Catalyst, on top of the earlier funding from our key investors, enables us to test this exciting new mechanism for the first time in atopic dermatitis and could provide the first safe, oral, once a day therapy for this disease. Furthermore, since the mechanism is also effective in asthma and allergic rhinitis this would provide a “one-stop” solution for those patients suffering from multiple co-existing allergies, whose only long term alternative at present is multiple topical therapy, usually involving steroids.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!